KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Total Non-Current Liabilities (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $768.3 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Total Non-Current Liabilities changed N/A year-over-year to $768.3 million, compared with a TTM value of $768.3 million through Jun 2023, changed N/A, and an annual FY2022 reading of $792.2 million, up 69.41% over the prior year.
  • Total Non-Current Liabilities was $768.3 million for Q2 2023 at Ginkgo Bioworks Holdings, down from $780.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q1 2021 and bottomed at $202.1 million in Q4 2020.
  • Average Total Non-Current Liabilities over 4 years is $683.4 million, with a median of $768.3 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 131.42% in 2021, then grew 23.88% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $202.1 million in 2020, then surged by 131.42% to $467.6 million in 2021, then surged by 69.41% to $792.2 million in 2022, then dropped by 3.01% to $768.3 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for DNA at $768.3 million in Q2 2023, $780.3 million in Q1 2023, and $792.2 million in Q4 2022.